Briefing
MolDX lists Signatera for recurrence testing in muscle-invasive bladder cancer
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for progression, recurrence, or relapse testing in muscle-invasive bladder cancer.